Pegylated interferon-αalpha monotherapy leads to low response rates in HIV-infected patients with acute hepatitis C

Antiviral Therapy

Volumn 16, Issue 7, 2011, Pages 979-988

  Arends, Joop E ^a   Van Assen, Sander ^b   Stek, Cari J ^b   Wensing, Annemarie M J ^a   Fransen, Justin H ^a   Schellens, Ingrid M ^a   Spijkers, Sanne N M ^a   Mudrikova, Tania ^a   Van Baarle, Debbie ^a   Sprenger, Herman G ^b   Hoepelman, Andy I M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ALLELE; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG EFFICACY; DRUG RESPONSE; GENE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IL28B GENE; MALE; MONOTHERAPY; MULTICENTER STUDY; NETHERLANDS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; SEQUENCE ANALYSIS; VIRAL CLEARANCE; VIREMIA; VIRUS LOAD;

ADULT; ALLELES; ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 80055100601     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1843     Document Type: Article

References (44)

1. Danta M, Brown D, Bhagani S, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007; 21:983-991. (Pubitemid 46684329)
2. Matthews GV, Hellard M, Kaldor J, Lloyd A, Dore GJ. Further evidence of HCV sexual transmission among HIVpositive men who have sex with men: response to Danta et al. AIDS 2007; 21:2112-2113. (Pubitemid 47462165)
3. Urbanus AT, van de Laar TJ, Stolte IG, et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS 2009; 23:F1-F7.
4. van de Laar TJ, van der Bij AK, Prins M, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis 2007; 196:230-238. (Pubitemid 47047462)
5. Rockstroh JK, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9:82-88. (Pubitemid 351228130)
6. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21:1073-1089. (Pubitemid 46763278)
7. Calleri G, Cariti G, Gaiottino F, et al. A short course of pegylated interferon-alpha in acute HCV hepatitis. J Viral Hepat 2007; 14:116-121. (Pubitemid 46146706)
8. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345:1452-1457.
9. Wiegand J, Buggisch P, Boecher W, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 2006; 43:250-256.
10. Arends JE, Schrover IM, Schaar CG, Mudrikova T, Hoepelman AI. Peginterferon monotherapy for the treatment of acute hepatitis C in HIV-coinfected patients. AIDS 2008; 22:1381-1382.
11. Vogel M, Rockstroh JK. Treatment of acute hepatitis C in HIV infection. J Antimicrob Chemother 2010; 65:4-9.
12. Dominguez S, Ghosn J, Valantin MA, et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS 2006; 20:1157-1161. (Pubitemid 43786104)
13. Fierer DS, Fishman S, Uriel AJ, et al. Characterization of an Outbreak of Acute HCV Infection in HIV-infected Men in New York City. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, QC, Canada. Abstract 802.
14. Gilleece YC, Browne RE, Asboe D, et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegylated interferon and ribavirin. J Acquir Immune Defic Syndr 2005; 40:41-46. (Pubitemid 41233203)
15. Lambers F, van den Berk G, van der Meer J, et al. Treatment Outcome of Acute Hepatitis C Virus Infection in HIV-infected MSM: The Effect of Treatment Length. 17th Conference on Retroviruses and Opportunistic Infections. 16-19 February 2010, San Francisco, CA, USA. Abstract 641.
16. Luetkemeyer A, Hare CB, Stansell J, et al. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr 2006; 41:31-36. (Pubitemid 41786016)
17. Matthews GV, Hellard M, Haber P, et al. Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis 2009; 48:650-658.
18. Schnuriger A, Dominguez S, Guiguet M, et al. Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus. AIDS 2009; 23:2079-2089.
19. Danta M, Turner JM, Johnstone R, et al. Use of pegylated interferon-alpha (peg-IFN) with or without ribavirin in the treatment of acute HCV in HIV-positive individuals. HIV Med 2005; 6:14-55.
20. De Rosa FG, Mollaretti O, Audagnotto S, et al. Efficacy of early pegylated interferon alpha-2b monotherapy for acute hepatitis C in HIV-infected patients. Clin Infect Dis 2009; 48:1636-1637.
21. Schulze zur Wiesch J, Pieper D, Stahmer I, et al. Sustained virological response after early antiviral treatment of acute hepatitis C virus and HIV coinfection. Clin Infect Dis 2009; 49:466-472.
22. Serpaggi J, Chaix ML, Batisse D, et al. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS 2006; 20:233-240.
23. Vogel M, Bieniek B, Jessen H, et al. Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases. J Viral Hepat 2005; 12:207-211. (Pubitemid 40342180)
24. Vogel M, Nattermann J, Baumgarten A, et al. Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals. Antivir Ther 2006; 11:1097-1101. (Pubitemid 44955186)
25. Morin T, Pariente A, Lahmek P, Rabaud C, Silvain C, Cadranel JF. Acute hepatitis C: analysis of a 126-case prospective, multicenter cohort. Eur J Gastroenterol Hepatol 2010; 22:157-166.
26. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798-801.
27. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
28. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferonalpha and ribavirin therapy. Nat Genet 2009; 41:1100-1104.
29. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138:1338-1345.
30. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferonalpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-1109.
31. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42:615-624.
32. Arends JE, Mudrikova T, Wensing AMJ, Wind CM, van Baarle D, Hoepelman AIM. High percentage of nonresponse with peginterferon-alfa-2a monotherapy for the treatment of acute hepatitis C in HIV infected patients. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 12-15 September 2009, San Francisco, CA, USA. Abstract 2458.
33. Katoh K, Asimenos G, Toh H. Multiple alignment of DNA sequences with MAFFT. Methods Mol Biol 2009; 537:39-64.
34. Asselah T. Genetic polymorphism and response to treatment in chronic hepatitis C: the future of personalized medicine. J Hepatol 2010; 52:452-454.
35. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatmentinduced viral clearance. Gastroenterology 2003; 125:80-88. (Pubitemid 36799109)
36. Tai AW, Chung RT. Treatment failure in hepatitis C: mechanisms of non-response. J Hepatol 2009; 50:412-420.
37. Núñez M, Miralles C, Berdun MA, et al. Role of weightbased ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007; 23:972-982. (Pubitemid 47492337)
38. Martin P, Jensen DM. Ribavirin in the treatment of chronic hepatitis C. J Gastroenterol Hepatol 2008; 23:844-855. (Pubitemid 351806583)
39. Morello J, Rodriguez-Novoa S, Jimenez-Nacher I, Soriano V. Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. J Antimicrob Chemother 2008; 62:1174-1180.
40. Thompson AJ, Fellay J, Patel K, et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 2010; 139:1181-1189.
41. Asselah T, Estrabaud E, Bieche I, et al. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int 2010; 30:1259-1269.
42. Nattermann J, Vogel M, Baumgarten A, et al. Genetic variation in IL28B and treatment-induced clearance of HCV in HCV/ HIV co-infected patients. 17th Conference on Retroviruses and Opportunistic Infections. 16-19 February 2010, San Francisco, CA, USA. Abstract 164.
43. Chen L, Borozan I, Feld J, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005; 128:1437-1444. (Pubitemid 40712193)
44. Younossi ZM, Baranova A, Afendy A, et al. Early gene expression profiles of patients with chronic hepatitis C treated with pegylated interferon-alfa and ribavirin. Hepatology 2009; 49:763-774.